scispace - formally typeset
Search or ask a question
Author

Walter T. Barry

Bio: Walter T. Barry is an academic researcher from Rockefeller University. The author has contributed to research in topics: Hepatitis C virus & Virus. The author has an hindex of 4, co-authored 4 publications receiving 969 citations.

Papers
More filters
Journal ArticleDOI
09 Jun 2011-Nature
TL;DR: It is demonstrated that HCV can be blocked by passive immunization, as well as showing that a recombinant vaccinia virus vector induces humoral immunity and confers partial protection against heterologous challenge.
Abstract: Hepatitis C virus (HCV) remains a major medical problem. Antiviral treatment is only partially effective and a vaccine does not exist. Development of more effective therapies has been hampered by the lack of a suitable small animal model. Although xenotransplantation of immunodeficient mice with human hepatocytes has shown promise, these models are subject to important challenges. Building on the previous observation that CD81 and occludin comprise the minimal human factors required to render mouse cells permissive to HCV entry in vitro, we attempted murine humanization via a genetic approach. Here we show that expression of two human genes is sufficient to allow HCV infection of fully immunocompetent inbred mice. We establish a precedent for applying mouse genetics to dissect viral entry and validate the role of scavenger receptor type B class I for HCV uptake. We demonstrate that HCV can be blocked by passive immunization, as well as showing that a recombinant vaccinia virus vector induces humoral immunity and confers partial protection against heterologous challenge. This system recapitulates a portion of the HCV life cycle in an immunocompetent rodent for the first time, opening opportunities for studying viral pathogenesis and immunity and comprising an effective platform for testing HCV entry inhibitors in vivo.

405 citations

Journal ArticleDOI
TL;DR: AFC8-hu HSC/Hep mice are a useful model of HCV infection, the immune response, and liver disease because they contain human immune system and liver cells and might also be used to develop therapeutics forHCV infection.

298 citations

Journal ArticleDOI
17 Mar 2011-Blood
TL;DR: In conclusion, humanized NSG-SGM3 mice might serve as a useful model to study human regulatory T-cell development in vivo, but this unexpected lineage skewing also highlights the importance of adequate spatiotemporal expression of human cytokines for future xenorecipient strain development.

254 citations

Journal ArticleDOI
TL;DR: It is suggested that the cellular IFN response plays a significant role in limiting the spread of HCV infection in primary hepatocyte cultures, enabling studies of virus pathogenicity and the mechanisms by which HCV spreads in its natural host cell population.

88 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: A mouse model recapitulating key features of CRS and neurotoxicity is described, offering a therapeutic strategy to tackle neurotoxicity and open new avenues to safer CAR T cell therapies.
Abstract: In the clinic, chimeric antigen receptor-modified T (CAR T) cell therapy is frequently associated with life-threatening cytokine-release syndrome (CRS) and neurotoxicity. Understanding the nature of these pathologies and developing treatments for them are hampered by the lack of appropriate animal models. Herein, we describe a mouse model recapitulating key features of CRS and neurotoxicity. In humanized mice with high leukemia burden, CAR T cell-mediated clearance of cancer triggered high fever and elevated IL-6 levels, which are hallmarks of CRS. Human monocytes were the major source of IL-1 and IL-6 during CRS. Accordingly, the syndrome was prevented by monocyte depletion or by blocking IL-6 receptor with tocilizumab. Nonetheless, tocilizumab failed to protect mice from delayed lethal neurotoxicity, characterized by meningeal inflammation. Instead, the IL-1 receptor antagonist anakinra abolished both CRS and neurotoxicity, resulting in substantially extended leukemia-free survival. These findings offer a therapeutic strategy to tackle neurotoxicity and open new avenues to safer CAR T cell therapies.

867 citations

01 Jan 2010
TL;DR: The data demonstrate a role for CD141+ DCs in the induction of cytotoxic T lymphocyte responses and suggest that they may be the most relevant targets for vaccination against cancers, viruses, and other pathogens.
Abstract: The characterization of human dendritic cell (DC) subsets is essential for the design of new vaccines. We report the first detailed functional analysis of the human CD141(+) DC subset. CD141(+) DCs are found in human lymph nodes, bone marrow, tonsil, and blood, and the latter proved to be the best source of highly purified cells for functional analysis. They are characterized by high expression of toll-like receptor 3, production of IL-12p70 and IFN-beta, and superior capacity to induce T helper 1 cell responses, when compared with the more commonly studied CD1c(+) DC subset. Polyinosine-polycytidylic acid (poly I:C)-activated CD141(+) DCs have a superior capacity to cross-present soluble protein antigen (Ag) to CD8(+) cytotoxic T lymphocytes than poly I:C-activated CD1c(+) DCs. Importantly, CD141(+) DCs, but not CD1c(+) DCs, were endowed with the capacity to cross-present viral Ag after their uptake of necrotic virus-infected cells. These findings establish the CD141(+) DC subset as an important functionally distinct human DC subtype with characteristics similar to those of the mouse CD8 alpha(+) DC subset. The data demonstrate a role for CD141(+) DCs in the induction of cytotoxic T lymphocyte responses and suggest that they may be the most relevant targets for vaccination against cancers, viruses, and other pathogens.

859 citations

Journal ArticleDOI
TL;DR: This Review discusses recent advances in the development and utilization of humanized mice, the lessons learnt, the remaining challenges and the promise of using humanization mice for the in vivo study of human immunology.
Abstract: Significant advances in our understanding of the in vivo functions of human cells and tissues and the human immune system have resulted from the development of 'humanized' mouse strains that are based on severely immunodeficient mice with mutations in the interleukin-2 receptor common γ-chain locus. These mouse strains support the engraftment of a functional human immune system and permit detailed analyses of human immune biology, development and functions. In this Review, we discuss recent advances in the development and utilization of humanized mice, the lessons learnt, the remaining challenges and the promise of using humanized mice for the in vivo study of human immunology.

842 citations

Journal ArticleDOI
TL;DR: In this paper, the authors review what is known about the pathogens that emerge, the hosts that they originate in, and the factors that drive their emergence and discuss challenges to their control and new efforts to predict pandemics.

751 citations

PatentDOI
27 Apr 2020-Science
TL;DR: The Grigoryan et al. show that natural and synthetic food dyes can be used as photoabsorbers that enable stereolithographic production of hydrogels containing intricate and functional vascular architectures, and establish intravascular and multivascular design freedoms with photopolymerizablehydrogels.
Abstract: A device made from a hydrogel matrix is provided. The hydrogel matrix includes a photoabsorber with a void architecture in the matrix, having a first vessel architecture and a second vessel architecture that are each tubular and branching, wherein the first and second vessel architectures are fluidically independent from each other. A pre-polymerization solution for forming the device, and methods of fabricating such devices are described. A method of fabricating a 3D hydrogel construct is provided. The method includes using a computer-implemented process to create a 3D model of the construct based on a tessellation of polyhedra having a number of faces connected by edges and vertices, generate a first vascular component of the model, generate a second vascular component of the model, and combine the first and second vascular components of the model.

712 citations